Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antioxidants and BH4 on Skin Blood Flow in African Americans
NCT03680573Phase 1Completed
- Sponsor
- The University of Texas at Arlington
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of sapropterin, apocynin and allopurinol in cardiovascular disease (CVD), sponsored by The University of Texas at Arlington. Started Jan 2018; status: completed.
02
Drugs
sapropterinapocyninallopurinol
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03680573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680573.